Mortality Reduction with GLP-1 Receptor Agonist Use in Type 2 Diabetes
Patientes with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality.
According to a study presented at CHEST 2025, a 20 percent greater mortality benefit is seen in the obstructive sleep apnea (OSA) population.
Patients with T2DM prescribed GLP-1 RAs have significantly lower one-year mortality, especially those also diagnosed with OSA.
- A total of 1,799,261 patients with T2DM who were prescribed metformin were identified.
- Patients were stratified into three groups: T2DM without OSA prescribed metformin without GLP-1 RAs (60.2 percent), T2DM without OSA prescribed metformin and GLP-1 RAs (20.1 percent), and T2DM with OSA prescribed metformin without GLP-1 RAs (11 percent).
Author's summary: GLP-1 RAs reduce mortality in T2DM patients, especially those with OSA.